SCHEMBL23217279

SCHEMBL23217279

COC(=O)/C=C/[C@@H]1C[C@H](c2c(OC)ccc(Cl)c2Cl)CN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.39
HTR2C P28335 5/20 0.39
HTR2B P41595 5/20 0.39
GRIN2B Q13224 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
DRD2 P14416 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
CLCN2 P51788 1/20 0.32
ANPEP P15144 2/20 0.31
MMP2 P08253 1/20 0.31
ATM Q13315 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217282 1.00 HTR2A (0.39) HTR2AHTR2CHTR2BGRIN2BKDM4E
SCHEMBL25034601 0.87 HTR2A (0.38) HTR2AHTR2CHTR2BALDH1A1ERBB2
SCHEMBL28827779 0.87 HTR2A (0.38) HTR2AHTR2CHTR2BALDH1A1ERBB2
SCHEMBL23217432 0.87 HTR2C (0.40) HTR2AHTR2CHTR2BGRIN2BDRD2
SCHEMBL23217433 0.87 HTR2C (0.40) HTR2AHTR2CHTR2BGRIN2BDRD2
SCHEMBL23217190 0.87 HTR2C (0.41) HTR2AHTR2CHTR2BKDM4EDRD2
SCHEMBL23217149 0.85 HTR2C (0.45) HTR2AHTR2CHTR2BKDM4EDRD2
SCHEMBL23217318 0.84 HTR2C (0.41) HTR2AHTR2CHTR2BDRD2ALDH1A1
SCHEMBL23217480 0.78 HTR2C (0.44) HTR2AHTR2CHTR2BDRD2ANPEP
SCHEMBL23217172 0.78 HTR2C (0.44) HTR2AHTR2CHTR2BDRD2ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 HTR2A 1799/4885HTR2C 1162/4885HTR2B 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.